PRNewsWire
29 Jun 2026, 01:27 UTC · 3h ago
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
29 Jun 2026, 01:27 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Harbour BioMed has appointed Dr. Lloyd Klickstein, a recognized rheumatologist and immunologist with a history of successful exits (Versanis Bio acquired by Eli Lilly), as Scientific Advisor for Immunology. — Adding high-caliber leadership with a track record of M&A success and deep Novartis experience increases the probability of pipeline success and potential future partnerships/acquisitions.
+0.30The company is focusing on accelerating the development of next-generation antibody therapies specifically within its immunology pipeline. — This signals a strategic prioritization of the immunology sector, though it is a general directional goal rather than a specific clinical milestone.
+0.10Which stocks this story touches
The company is strengthening its immunology pipeline by appointing a highly experienced scientific advisor.
Continue reading
6 related stories
Search tags
The company is mentioned only as the acquirer of a previous company founded by the new advisor.
The company is mentioned only as a former employer of the new advisor.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Fox Business
2h ago
